Φορτώνει......
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies
BACKGROUND: Pre-exposure prophylaxis (PrEP) using antiretroviral (ARV) agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the...
Αποθηκεύτηκε σε:
Τόπος έκδοσης: | J Acquir Immune Defic Syndr |
---|---|
Κύριοι συγγραφείς: | , , , , , , , , |
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
2016
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5123706/ https://ncbi.nlm.nih.gov/pubmed/27792681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001119 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|